Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant

✍ Scribed by Hideki Hasegawa; Takeshi Ichinohe; Peter Strong; Izumi Watanabe; Satoshi Ito; Shin-ichi Tamura; Hidehiro Takahashi; Hirofumi Sawa; Joe Chiba; Takeshi Kurata; Tetsutaro Sata

• Publisher: John Wiley and Sons
• Year: 2004
• Tongue: English
• Weight: 106 KB
• Volume: 75
• Category: Article
• ISSN: 0146-6615
• DOI: 10.1002/jmv.20247

✦ Synopsis

Abstract

Chitin in the form of microparticles (chitin microparticles, CMP) has been demonstrated to be a potent stimulator of macrophages, promoting T‐helper‐1 (Th1) activation and cytokine response. In order to examine the mucosal adjuvant effect of CMP co‐administered with influenza hemagglutinin (HA) vaccine against influenza infection, CMP were intranasally co‐administered with influenza HA vaccine prepared from PR8 (H1N1) virus. Inoculation of the vaccine with CMP induced primary and secondary anti‐HA IgA responses in the nasal wash and anti‐HA IgG responses in the serum, which were significantly higher than those of nasal vaccination without CMP, and provided a complete protection against a homologous influenza virus challenge in the nasal infection influenza model. In addition, CMP‐based immunization using A/Yamagata (H1N1) and A/Guizhou (H3N2) induced PR8 HA‐reactive IgA in the nasal washes and specific‐IgG in the serum. The immunization with A/Yamagata and CMP resulted in complete protection against a PR8 (H1N1) challenge in A/Yamagata (H1N1)‐vaccinated mice, while that with A/Guizhou (H3N2) and CMP exhibited a 100‐fold reduction of nasal virus titer, demonstrating the cross‐protective effect of CMP and influenza vaccine. It is suggested that CMP provide a safe and effective adjuvant for nasal vaccination with inactivated influenza vaccine. J. Med. Virol. 75:130–136, 2005. © 2005 Wiley‐Liss, Inc.